Results 61 to 70 of about 4,435,862 (297)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Direct oral anticoagulants in cancer-associated venous thromboembolism

open access: yesVascular Investigation and Therapy, 2020
This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and treatment of venous thromboembolism (VTE) in cancer patients.
Kirill Lobastov   +2 more
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen   +14 more
wiley   +1 more source

Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem

open access: yesРациональная фармакотерапия в кардиологии, 2019
The review focuses on the use of oral anticoagulants in fragile elderly patients. The issues of prevalence and diagnosis of senile asthenia syndrome or “fragility”, as well as its effects on the risks of thrombosis, bleeding and death, are discussed. The
N. M. Vorobyeva, O. N. Tkacheva
doaj   +1 more source

Direct Oral Anticoagulants in the Real World

open access: yes, 2017
Background Direct oral anticoagulants are convenient because of their fixed dosing and without laboratory monitoring. There are instructions on avoidance of moisture, no crushing of capsules, and administration with food for some direct oral ...
Sam Schulman   +5 more
core   +1 more source

Applying machine learning to pharmacovigilance data: A proof‐of‐concept study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Machine learning (ML) applications in pharmacovigilance remain limited and underexplored. Using data from the French National pharmacovigilance database (FNPV), this proof‐of‐concept study aimed to assess the feasibility of using a ML algorithm—eXtreme Gradient Boosting (XGBoost)—combined with SHapley Additive exPlanations (SHAP) analysis, to ...
Romain Barus   +6 more
wiley   +1 more source

Role of direct oral anticoagulants in gastrointestinal cancerassociated thrombosis "gpractical issues in clinical practice"—narrative review

open access: yes
Objective: Direct oral anticoagulants (DOAC) are now considered an effective treatment option for cancer associated thrombosis (CAT). There are still controversies in the use of DOACs in CAT associated with gastrointestinal (GI) malignancies. Background:
Mahmood, Shahid   +4 more
core   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu   +7 more
wiley   +1 more source

Measurement and reversal of the direct oral anticoagulants [PDF]

open access: yesBlood Reviews, 2017
Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
Bethany T, Samuelson, Adam, Cuker
openaire   +2 more sources

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy